MedTrace Logo

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

NCT02555124 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-03-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of JNJ-42847922 following single oral administration.

Conditions

  • Healthy

Interventions

DRUG

JNJ-42847922, 5 mg

Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.

DRUG

JNJ-42847922, 20 mg

Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.

DRUG

JNJ-42847922, 40 mg

Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.

DRUG

Placebo

Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.

Sponsors & Collaborators

  • Janssen Pharmaceutical K.K.

    lead INDUSTRY

Principal Investigators

  • Janssen Pharmaceutical K.K., Japan Clinical Trial · Janssen Pharmaceutical K.K.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-12
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02555124 on ClinicalTrials.gov